In a narrow, closely watched vote that has sparked widespread debate across the U.S. wellness and medical communities, a special advisory committee convened by the U.S. Food and Drug Administration (FDA) has backed rolling back existing restrictions on a group of controversial, understudied peptides that have exploded in popularity on social media platforms in recent years.
The panel’s 5-4 decision clears a key path for specialized compounding pharmacies—facilities that customize medications not manufactured by mainstream pharmaceutical companies—to produce three of the most high-profile compounds in question: BPC-157, TB-500, and KPV, bringing them one step closer to becoming available by prescription for American patients.
Peptides, short amino acid chains that function as naturally occurring signaling proteins in the human body, have a long history of safe, regulated use in evidence-based medicine, ranging from diabetes treatment to hormone therapy. But the rise of unregulated injectable peptides took off after GLP-1 weight loss drugs entered the mainstream, with the trend spreading rapidly across online wellness communities and being amplified by millions of young social media influencers.
Platforms like TikTok have turned unapproved peptides into a viral trend, particularly among teen and young adult boys, where influencers market peptide “stacks” with unproven claims ranging from slowing skin aging and accelerating injury healing to building muscle mass. Users have embraced the practice as part of online “biohacking” and “looksmaxxing” subcultures that prioritize quick physical enhancements, leading to soaring unregulated online sales of the compounds.
To date, none of the popular peptides at the center of the FDA debate have completed large-scale rigorous clinical trials to confirm their safety or effectiveness for human use. Health experts and anti-doping agencies have repeatedly issued urgent warnings about the unmonitored use of these substances, noting that their long-term health impacts remain completely unknown.
BPC-157, the most widely promoted of the peptides, is derived from a natural stomach protein. Influencers market it as a treatment for gut inflammation, tissue damage repair, and muscle recovery, and it has only undergone limited testing in animal models for muscle healing potential. Both the U.S. Anti-Doping Agency and the World Anti-Doping Agency have designated BPC-157 a banned performance-enhancing substance, with USADA explicitly stating that “no-one knows if there is a safe dose, or if there is any way to use this compound safely to treat specific medical conditions.” KPV, another popular peptide, is similarly marketed for gut health, acne reduction, and immune regulation, with no conclusive human trial data to back these claims.
For years, the peptides have operated in a regulatory grey area: they are not illegal to purchase or possess, and are widely sold through unregulated online platforms, but they have never received FDA approval for human use, meaning they are not held to the strict manufacturing quality and safety standards that apply to approved prescription medications. Restrictions on the compounds were first implemented during the Biden administration after FDA regulators concluded they failed to meet baseline safety requirements.
U.S. Health Secretary Robert F. Kennedy Jr., a self-described “big fan” of these peptides, made rolling back these restrictions a top priority after taking office, and has repeatedly pledged to loosen regulations on the fast-growing peptide industry. While the FDA is not legally required to adopt the advisory panel’s recommendations, it typically follows the panel’s guidance in most regulatory decisions.
The vote exposed deep divisions among committee members. Panel member Elizabeth Rebello, a practicing pharmacist and anesthesiologist, told the committee she voted against approving BPC-157 due to “the lack of efficacy data” and persistent “safety concerns,” according to reporting from Reuters. Supporters of the rollback, meanwhile, cited arguments around “medical freedom” and “the greater good” of expanding access to potential treatments to justify their votes. Notably, several panel members hold professional ties to clinics and businesses that sell peptide products. The committee is scheduled to continue deliberations on the full set of seven peptides under review on Friday.